Status: Recruiting
A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors
Phase Ib: Explore the safety and tolerability of BL-M07D1 to further define RP2D in a variety of solid tumors, including locally advanced or metastatic urinary and gastrointestinal tumors. Phase II: To explore the efficacy of BL-M07D1 in patients with a variety of solid tumors including locally advanced or metastatic HER2-positive/low-expressing urinary and gastrointestinal tumors.
Participants needed: 42
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Sichuan Baili Pharmaceutical Co., Ltd.Updated: Apr 8, 2026Locations: 1
Eligibility criteria
Voluntarily sign the informed consent form and comply with the protocol requirem... [+14]
Received chemotherapy, biological therapy, immunotherapy, or other antitumor tre... [+17]